Visual prognosis and risk factors for Korean patients with Behcet uveitis

Ophthalmologica

Volumn 222, Issue 5, 2008, Pages 344-350

  Cho, Young Jae ^a   Kim, Wook Kyum ^a   Lee, Jong Hyun ^b   Byeon, Suk Ho ^a   Koh, Hyoung Jun ^a   Kwon, Oh Woong ^a   Lee, Sung Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Inje University   (South Korea)

Author keywords

Behcet uveitis; Visual acuity; Visual prognosis

Indexed keywords

AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; INFLIXIMAB; INTERFERON; METHOTREXATE;

ADOLESCENT; ADULT; ARTICLE; BEHCET DISEASE; CHILD; CONTROLLED STUDY; FEMALE; HUMAN; KAPLAN MEIER METHOD; KOREA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; RISK FACTOR; SEX DIFFERENCE; UVEITIS; VISUAL ACUITY;

ADOLESCENT; ADULT; BEHCET SYNDROME; CHILD; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; KAPLAN-MEIERS ESTIMATE; KOREA; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; UVEITIS; VISUAL ACUITY;

EID: 47149085151     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000146080     Document Type: Article

References (26)

1. Michelson JB, Chisari FV: Behcet's disease. Surv Ophthalmol 1982;26:190-203.
2. Sakane T, Takeno M, Suzuki N, Inaba G: Behcet's disease. N Eng J Med 1999;341:1284-1291.
3. Caca I, Nazaroglu H, Unlu K, Cakmak SS, Ari S, Sakalar YB: Color doppler imaging of ocular hemodynamic changes in Behcet's disease. Jpn J Ophthalmol 2004;48:101-105.
4. Tuqal-Tutkun I, Onal S, Altan-Yaycioqlu R, Huseyin A H, Urqancioqlu M: Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol 2004;138:373-380.
5. Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, Ando K, Hijikata K, Izawa Y, Hayashi K, Numaga J, Fujino Y, Masuda K, Araie M: Comparison of patients with Behcet's disease in the 1980s and 1990s. Ophthalmology 2004;111:810-815.
6. Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, Usui M: Risk and prognostic factors of poor visual outcome in Behcet's disease with ocular involvement. Graefes Arch Clin Exp Ophthalmol 2005;243:1147-1152.
7. Evereklioqlu C: Current concepts in the etiology and treatment of Behcet disease. Surv Ophthalmol 2005;50:297-350.
8. Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M: Results of interferon-alfa therapy in patients with Behcet uveitis. Graefes Arch Clin Exp Ophthalmol 2006;244:1692-1695.
9. Murray PI, Sivaraj RR: Anti-TNF-alpha therapy for uveitis: Behcet and beyond. Eye 2005;19:831-833.
10. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ: Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449-1453.
11. Lindstedt EW, Baarsma GS, Kuijpers RW, van Hagen PM: Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol 2005;89:533-536.
12. Behcet's Disease Research Committee of Japan: The Revised Criteria and Manual of Treatments of Behcet's Disease. Tokyo, Ministry of Health and Welfare, 2003, pp 11-29.
13. Demiroglu H, Barista I, Dundar S: Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey. Ophthalmology 1997;104:701-705.
14. Sakamoto M, Akazawa K, Nishioka Y, Sanui H, Inomato H, Nose Y: Prognostic factors of vision in patients with Behcet's disease. Ophthalmology 1995;102:317-321.
15. Ando K, Fujino Y, Hijikata K, Izawa Y, Masuda K: Epidemiological features and visual prognosis of Behcet's disease. Jpn J Ophthalmol 1999;43:312-317.
16. Yurdakul S, Hamuryudan V, Yazici H: Behcet syndrome. Curr Opin Rheumatol 2004;16:38-42.
17. Tursen U, Gurler A, Boyvat A: Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet's disease. Int J Dermatol 2003;42:346-351.
18. Ozdal PC, Ortac S, Taskintuna I, Firat E: Posterior segment involvement in ocular Behcet's disease. Eur J Ophthalmol 2002;12:424-431.
19. El Ramahi KM, Al Dalaan A, Al Shaikh A, Al Meshari K, Akhtar M: Renal involvement in Behcet's disease: review of 9 cases. J Rheumatol 1998;25:2254-2260.
20. Kazokoglu H, Saatci O, Cuhadaroglu H, Eldem B: Long-term effects of cyclophosphamide and colchicine treatment in Behcet's disease. Ann Ophthalmol 1991;23:148-151.
21. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G: Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behcet's disease. Lancet 1989;i:1093-1096.
22. Hirohata S: Is the long-term use of systemic corticosteroids beneficial in the management of Behcet's syndrome? Nat Clin Pract Rheumatol 2006;2:358-359.
23. Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K: Behcet's disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc 1979;77:225-279.
24. Kötter I, Günaydin I, Zierhut M, Stübiger N: The use of interferon alfa in Behcet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-335.
25. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, Schlincker A, Martin-Mola E: Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 2001;358:1644.
26. Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, Piette JC, LeHoang P: Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocul Immunol Inflamm 2000;8: 293-301.